Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this intervention clinical trial is to learn about the protection of isomaltooligosaccharides (IMO) on intestinal bacterial translocation in patients with liver cirrhosis. The main question is to answer the changes of LPS after adminstration of IMO.
Eligibility Criteria
Inclusion Criteria: * Age from 18-75. * Cirrhotic patients. * Decompensation event: ascites. * LPS\>0.45EU/ml. Exclusion Criteria: * Pregnant or breast-feeding. * Active bacterial or fungal infection. * Other decompensations: Hepatic encephalopathy, gastroesophageal varices and hemorrhage. * Diagnosis of EASL-ACLF. * Diarrhea. * Malignancy. * Anticipated short survival time. * Adverse reactions or allergies to oral carbohydrate preparations. * Substance abuse or addiction. * Severe extrahepatic diseases (e.g. patients with CKD-5 stage, severe cardiopulmonary dysfunction, and psychiatric disorders). * Be immunosuppressed or immunodeficient states and the use of immunoglobulins or other immune-boosting conditions. * Be unsuitable for participating in this trial. * Participated in any drug trial within the past month * History of antibacterial or fungal use within 1 week prior to screening